Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Confe... ( PRINCETON N.J. July 1 /- In conju...)

Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Conference Call

Date:7/1/2008

PRINCETON, N.J., July 1 /PRNewswire-FirstCall/ -- In conjunction with its second quarter 2008 earnings release (expected to be issued after market close on July 30), Covance Inc. (NYSE: CVD) is pleased to invite you to listen to its quarterly investor conference call that will be broadcast live over the Internet on Thursday, July 31, 2008 at 9:00 a.m. ET.

What: Covance Second Quarter 2008 Earnings Webcast and Slide

Presentation

When: July 31, 2008, 9:00 a.m. ET*

Where: http://www.covance.com

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

*If you are unable to participate during the live webcast, the event will be archived on the web site http://www.covance.com for 14 days.

SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/6/2009)... NEW ORLEANS, Dec. 6 Blood clotting, ... excessive bleeding when a blood vessel is injured. ... vessels without an obvious injury or do not ... Research presented today at the 51st Annual Meeting ... the practice of using the anticoagulants aspirin and ...

(Date:12/6/2009)... the Greater VA Healthcare System in West Los Angeles, will once ... soar to more than 5,000 veterans, active military personnel and their ... ... -- Volunteer organizations and members of the community, in cooperation with ... again create a holiday party. This year,s attendance is expected to ...

(Date:12/5/2009)... There have been significant scientific advances in the ... gain a better understanding of how certain diseases progress ... patients with the best care. Research presented today at ... Hematology explores optimal induction therapies for managing multiple myeloma, ...

(Date:12/5/2009)... Cancer Is Most Challenging-- ,, PHILADELPHIA and ... specific genes, dubbed partner genes, that fuse with another ... infants. By more accurately defining specific partner genes, researchers ... particular treatments. ,, Oncologists also aim to use ...

(Date:12/5/2009)... with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) ... birthday without ever tying the knot, since research has shown ... And, um, isn,t there something wrong with those who go ... study looking at psychological measures shows that never-married people aged ...

Breaking Medicine News(10 mins):Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7 Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2 Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8 Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2 Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3 Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4 Health News:Never Married, Over 40, Well-Adjusted 2 Health News:Never Married, Over 40, Well-Adjusted 3

[0] Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages [0] 17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” [0] New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer [0] New Gene Findings Will Help Guide Treatment in Infant Leukemia [0] Never Married, Over 40, Well-Adjusted

... KIBBUTZ SHAMIR, Israel, March 6 Shamir,Optical Industry Ltd. ... products and technology to the progressive ophthalmic lens,market, today ... ended December 31, 2007., For the fourth quarter ... revenues of $25.4 million for the fourth quarter of,2006. ...

... Net Revenues up 23%, Adjusted EBITDA up 33%, ... NYSE:,MDZ), a leading provider of products and services to ... 2008 results. For the,quarter, MDS reported net revenues of ... share from continuing operations of $0.14.,Adjusted EBITDA rose to ...

... The International,Society for CNS Clinical Trials ... in Washington, DC, February 25-27. This organization,involves ... of the pharmaceutical industry, and governmental,drug-regulatory bodies ... safety,of drugs used to treat psychiatric and ...

... Sponsor for Toxin-Free Pain Relief, PLEASANT GROVE, Utah, ... relief cream Myo-Med ( http://www.myomed.com ),received overwhelming praise from ... Arizona relay course on February 29 and March 1.,The ... 187 mile relay event run by,12-person teams over a ...

... Tests That Can Prevent Colon Cancer, Including,Colonoscopy, ... new guideline on,colorectal cancer screening released today ... of health care organizations, including the American,College ... Endoscopy (ASGE) and the American Cancer Society ...

... Letter asks Senate Budget Leaders to Reject Oxygen ... Reform Much More Difficult,to Achieve, Letter Draws ... March 5 The Council for Quality,Respiratory Care ... home oxygen,therapy providers and manufacturers who provide care ...

Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2007 Results MDS Reports First Quarter 2008 Results FDA Warning of Suicidal Risk Associated with Antidepressants in Juveniles and Young Adults Reviewed at Recent ISCTM Meeting Myo-Med Makes Splash at Ragnar Relay New Guidelines Update Recommendations on Colorectal Cancer Screening Home Oxygen Community Applauds Senator Tim Johnson for Joining Bi-Partisan Effort to Formally Oppose Proposed Cuts to Medicare's Home Oxygen Benefit

(Date:12/4/2009)... Inc. (NYSE: HSP ), a leading global ... launch of its next-generation 50 mL and 100 mL ... now offers a complete size range (50 mL to ... The launch of the 50 mL and 100 mL ...

(Date:12/4/2009)... 4 Axsun Technologies, Inc., a wholly-owned subsidiary of ... initial development and successful testing of a novel integrated ... this proprietary optical engine design raises the bar on ... for swept source OCT light sources. This approach ...

(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...

Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2 Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3 Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4 Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2 Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3 Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4 Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5 Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2 Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3 Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4 Online Store Offers Affordable Digital Hearing Aids For Baby Boomers 48986 1 Online Store Offers Affordable Digital Hearing Aids For Baby Boomers 48986 2 Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 48984 1 Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 48984 2 Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 48984 3 A STAR scientists invent the worlds only controllable molecule gear of minuscule size of 1 2nm 12637 1 A STAR scientists invent the worlds only controllable molecule gear of minuscule size of 1 2nm 12637 2

[0] Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers [0] Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging [0] Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial

... into phase IIb study, called POLI 1 -, ... Roche,s new,investigational drugs for chronic hepatitis C virus ... in combination with,PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), ... for the Study of the,Liver Disease (AASLD) meeting, ...

... IDM-2101 showed an improvement in median survival vs. ... parallel external controls -, ... ) today announced updated results from the Phase 2 study of,its ... specific cytotoxic T lymphocyte (CTL) responses,and showed a positive survival trend ...

Other Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2 Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3 Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4 Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5 Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6 Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7 IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 2 IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 3 IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 4

Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Pb, Blood Parvovirus B19 Antibody, IgM Paxil Parvovirus B 19, by PCR, Bone Marrow

Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Confe...( PRINCETON N.J. July 1 /- In conju...),Health